BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 24892254)

  • 1. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
    Pal SK; Hu A; Chang M; Figlin RA
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.
    Harshman LC; Drake CG; Choueiri TK
    Cancer Immunol Res; 2014 Dec; 2(12):1132-41. PubMed ID: 25480555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
    Buti S; Bersanelli M
    Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
    [No Abstract]   [Full Text] [Related]  

  • 7. PD-1/PD-L1 inhibitors.
    Sunshine J; Taube JM
    Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The science of checkpoint inhibition in kidney cancer.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):214-7. PubMed ID: 27166601
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical use of checkpoint inhibition in kidney cancer.
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):427-9. PubMed ID: 27379812
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition].
    Oppel-Heuchel H; Grimm MO
    Urologe A; 2016 May; 55(5):677-90. PubMed ID: 27146870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
    Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
    Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
    Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
    Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for targeting PD-1 and PD-L1 in various tumor types.
    Kim JW; Eder JP
    Oncology (Williston Park); 2014 Nov; 28 Suppl 3():15-28. PubMed ID: 25387682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 inhibition with MPDL3280A for solid tumors.
    Cha E; Wallin J; Kowanetz M
    Semin Oncol; 2015 Jun; 42(3):484-7. PubMed ID: 25965367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
    Joseph RW; Millis SZ; Carballido EM; Bryant D; Gatalica Z; Reddy S; Bryce AH; Vogelzang NJ; Stanton ML; Castle EP; Ho TH
    Cancer Immunol Res; 2015 Dec; 3(12):1303-7. PubMed ID: 26307625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
    Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PD-1 therapy in melanoma.
    Homet Moreno B; Parisi G; Robert L; Ribas A
    Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.